Plain-English translation of NCT06550102 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are building a registry to help doctors personalize treatment for blood cancers like leukemia, lymphoma, and myeloma. They take cancer cells from your diagnostic sample and test them in the laboratory against many different chemotherapy drugs and targeted treatments to see which ones are most effective against your specific cancer. This information is then compared with how well you actually respond to treatment to help improve future care.
Not all patients with the same blood cancer respond the same way to treatment. By testing each patient's cancer cells against a variety of drugs before treatment starts, doctors hope to identify which medications will work best for that individual, potentially leading to better outcomes and fewer side effects.
You likely qualify if…
You likely don't qualify if…
As a participant, you would donate tumor material (blood or bone marrow) that is already being collected as part of your routine cancer diagnosis and treatment. Your doctors will share information about your cancer type, genetic features, and how you respond to the treatments you receive. The research team will test your cancer cells against different drugs in the lab and track how your disease responds to your actual treatment over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland
Sponsor
University Children's Hospital, Zurich
Enrollment target
~1,000 participants
Started
January 2022
Primary completion
December 2031
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jean-Pierre Bourquin, MD, PhD
University Children's Hospital Zurich
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.